Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease

References

• . Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dialysis. 2008;21(4):300–307
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Sandberg KR. Chronic kidney disease and sudden death: strategies for prevention. Blood Purif. 2004;22(1):136–142
   PubMed Web of Science ®Google Scholar
• . Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539
   PubMed Web of Science ®Google Scholar
• . Van Dokkum RP, Eijkelkamp WB, Kluppel AC, . Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol. 2004;15(12):3103–3110
   PubMed Web of Science ®Google Scholar
• . Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenic factor? J Am Coll Cardiol. 2006;47(1):1–8
   PubMed Web of Science ®Google Scholar
• . National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266
   PubMed Web of Science ®Google Scholar
• . McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens. 2004;13(6):591–600
   PubMed Web of Science ®Google Scholar
• . Adler AI, Stevens RJ, Manley SE, . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Li S, Jurkovitz CT, Stevens LA, ; Kidney Early Evaluation Program Investigators. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51(4 suppl 2):S38–S45
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Jurkovitz CT, Pergola PE, ; for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167(11):1122–1129
   PubMedGoogle Scholar
• . Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305
   PubMed Web of Science ®Google Scholar
• . Plantinga LC, Miller ER, Stevens LA, ; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999–2006. Hypertension. 2009;54(1):47–56
   PubMed Web of Science ®Google Scholar
• . Sarnak MJ, Levey AS, Schoolwerth AC, ; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–2169
   PubMed Web of Science ®Google Scholar
• . Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291–297
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Sandberg KR, Yee J, Hudson MP. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst. 2002;3(3):188–191
   PubMed Web of Science ®Google Scholar
• . Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol. 1997;8(11):1764–1770
   PubMed Web of Science ®Google Scholar
• . Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med. 2001;161(12):1492–1499
   PubMedGoogle Scholar
• . Brenner BM, Cooper ME, de Zeeuw D; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Parving HH, Lehnert H, Bröchner-Mortensen J; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Dahlof B, Devereux RB, Kjeldsen SE; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003
   PubMed Web of Science ®Google Scholar
• . Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629–636
   PubMed Web of Science ®Google Scholar
• . Hampl H, Sternberg C, Berweck S, . Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol. 2002;58( suppl 1):S73–S96
   PubMed Web of Science ®Google Scholar
• . Agodoa LY, Appel L, Bakris GL, ; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719–2728
   PubMed Web of Science ®Google Scholar
• . Mann JF, Schmieder RE, McQueen M, ; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553
   PubMed Web of Science ®Google Scholar
• . Fichett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag. 2009;5(1):21–29
   PubMedGoogle Scholar
• . Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cohrane Database Syst Rev. 2009;3:CD007004
   Google Scholar
• . McCullough PA. Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Circulation. 2006;114(1):6–7
   PubMed Web of Science ®Google Scholar
• . Young JB, Dunlap ME, Pfeffer MA, ; Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Circulation. 2004;110(17):2618–2626
   PubMed Web of Science ®Google Scholar
• . Li PK, Chow KM, Wong TY, . Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med. 2003;139(2):105–112
   PubMed Web of Science ®Google Scholar
• . Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003;16(9 pt 2):7S–12S
   PubMed Web of Science ®Google Scholar
• . Cice G, Ferrara L, D'Andrea A, . Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–1444
   PubMed Web of Science ®Google Scholar
• . Weber MA. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol. 2007;100(3A):45J–52J
   PubMed Web of Science ®Google Scholar
• . Unger T, Stoppelharr M. Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol. 2007;100:25J–31J
   PubMed Web of Science ®Google Scholar
• . Cohn JN, Goldman JM. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens. 2008;21(3):248–256
   PubMed Web of Science ®Google Scholar
• . Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther Adv Cardiovasc Dis. 2007;1(1):27–35
   PubMedGoogle Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet. 2007;370(9583):221–229
   PubMed Web of Science ®Google Scholar
• . Pool JL, Schmieder RE, Asisi M, . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1):11–20
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Sandberg KR, Borzak S, . Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 2002;144(2):226–232
   PubMed Web of Science ®Google Scholar
• . National Institutes of Health. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009
   Google Scholar
• . Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375–2384
   PubMed Web of Science ®Google Scholar
• . National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41( suppl 4):S1–S92
   PubMed Web of Science ®Google Scholar
• . Chen J, Muntner P, Hamm LL, . The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140(3):167–174
   PubMed Web of Science ®Google Scholar
• . Buemi M, Senatore M, Corica F, . Statins and progressive renal disease. Med Res Rev. 2002;22(1):76–84
   PubMed Web of Science ®Google Scholar
• . Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl. 1999;71:S2–S5
   PubMedGoogle Scholar
• . Keech A, Simes RJ, Barter P, ; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366(9500):1849–1861
   PubMed Web of Science ®Google Scholar
• . Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus—a pooled meta-analysis of randomized placebo-controlled clinical trials [published online ahead of print February 16, 2009]. Int J Cardiol
   Google Scholar
• . Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Curr Med Res Opin. 2009;22(3):617–623
   Google Scholar
• . Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009;65(12):1169–1174
   PubMed Web of Science ®Google Scholar
• . Tonelli M, Isles C, Curhan GC, . Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
   PubMed Web of Science ®Google Scholar
• . Tonelli M, Keech A, Shepherd J, . Effects of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748–3754
   PubMed Web of Science ®Google Scholar
• . Tonelli M, Isles C, Craven T, . Effect on pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112(2):171–178
   PubMed Web of Science ®Google Scholar
• . Navaneethan SD, Pansini F, Perkovic V, . HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;2:CD007784
   Google Scholar
• . Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y; MEGA Study Group. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206(2):512–517
   PubMed Web of Science ®Google Scholar
• . Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
   PubMed Web of Science ®Google Scholar
• . Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260–269
   PubMed Web of Science ®Google Scholar
• . Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–1690
   PubMed Web of Science ®Google Scholar
• . Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35(7–8):908–917
   PubMed Web of Science ®Google Scholar
• . Fellstrom BC, Jardine AG, Schmieder RE; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
   PubMed Web of Science ®Google Scholar
• . Wanner C, Krane V, März W, ; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Agarwal M, Agrawal V. Review article: risks of coronary artery calcification in chronic kidney disease: do the same rules apply? Nephrology (Carlton). 2009;14(4):428–436
   PubMed Web of Science ®Google Scholar
• . Hanratty R, Chonchol LM, Dickinson M, . Incidence chronic kidney disease and the rate of kidney function decline in individuals with hypertension [published online ahead of print November 4, 2009]. Nephrol Dial Translpant
   Google Scholar
• . Whaley-Connell AT, Sowers JR, McFarlane SI, ; Kidney Early Evaluation Program Investigators. Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51(S2):S21–S29
   PubMedGoogle Scholar
• . Gerstein HC, Mann JFE, Yi Q, ; HOPE study investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426
   PubMed Web of Science ®Google Scholar
• . Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Penderson O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
   PubMed Web of Science ®Google Scholar
• . Gaede P, Lund-Anderson H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
   PubMed Web of Science ®Google Scholar
• . Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag. 2009;5:859–871
   PubMedGoogle Scholar
• . Skyler JS, Bergenstal R, Bonow RO, ; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(4):187–192
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1588
   PubMed Web of Science ®Google Scholar
• . Brosius FC 3rd, Hostetter TH, Kelepouris E, . Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006;114(10):1083–1087
   PubMed Web of Science ®Google Scholar
• . Arnlöv J, Evans JC, Meigs JB, . Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals. Circulation. 2005;112(7):969–975
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Mann JF, Yi Q, ; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426
   PubMed Web of Science ®Google Scholar
• . de Zeeuw D, Remuzzi G, Parving HH, . Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921–927
   PubMed Web of Science ®Google Scholar
• . de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol. 2006;17(8):2120–2126
   PubMed Web of Science ®Google Scholar
• . Asselbergs FW, Diercks GF, Hillege HL, ; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809–2816
   PubMed Web of Science ®Google Scholar
• . Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care. 1996;19(6):625–628
   PubMed Web of Science ®Google Scholar
• . Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens. 2002;11(5):483–488
   PubMed Web of Science ®Google Scholar
• . Rigotti NA. Helping smokers with cardiac disease abstain from tobacco after a stay in hospital. CMAJ. 2009;180(13):1283–1284
   PubMed Web of Science ®Google Scholar
• . Spinler SA, Mahaffey KW, Gallup D, ; SYNGERY Trial Investigators. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY [published online ahead of print April 28, 2009]. Int J Cardiol
   Google Scholar
• . Vasu S, Gruberg L, Brown DL. The impact of advanced chronic kidney disease on in-hospital mortality following percutaneous coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2007;70(5):701–705
   PubMed Web of Science ®Google Scholar
• . Best PJ, Berger PB, Davis BR, ; PRESTO Investigators. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol. 2004;44(9):1786–1791
   PubMed Web of Science ®Google Scholar
• . Bonello L, DeLabriolle A, Roy P, . Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. Am J Cardiol. 2008;102(5):535–540
   PubMed Web of Science ®Google Scholar
• . Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high risk smokers with cardiovascular disease. Chest. 2007;131(2):464–452
   Web of Science ®Google Scholar
• . Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev. 2007;3:CD001837
   Google Scholar
• . Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197–2202
   PubMedGoogle Scholar
• . Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121(1):43–49
   PubMed Web of Science ®Google Scholar
• . Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126( 3 suppl):234S–264S
   PubMed Web of Science ®Google Scholar
• . Winchester JF. Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis. 1996;28(1 suppl 1):S20–S23
   PubMed Web of Science ®Google Scholar
• . Kaufman JS, Fiore L, Hasbargen JA, O'Connor TZ, Perdriset G. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis. 2000;10(2):127–231
   PubMed Web of Science ®Google Scholar
• . Best PJ, Steinhubl SR, Berger PB, ; CREDO investigators. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687–693
   PubMed Web of Science ®Google Scholar
• . Tadros GM, Herzog CA. Percutaneous coronary intervention in chronic kidney disease patients. J Nephrol. 2004;17(3):364–368
   PubMed Web of Science ®Google Scholar
• . Gibson CM, Pinto DS, Murphy SA, . Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003;42:1535–1543
   PubMed Web of Science ®Google Scholar
• . Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E; TACTICS-TIMI 18 Investigators. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002;90(11):1246–1249
   PubMed Web of Science ®Google Scholar
• . Ix JH, Mercado N, Shlipak MG, . Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS). Am Heart J. 2005;149(3):512–519
   PubMed Web of Science ®Google Scholar
• . Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799–805
   PubMed Web of Science ®Google Scholar
• . Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol. 2006;1(4):796–801
   PubMed Web of Science ®Google Scholar
• . Chayrtan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J. 2006;152(3):558–564
   PubMed Web of Science ®Google Scholar
• . Berter AK, Duval S, Krumholtz HM. Aspirin, beta-blockers, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201–208
   PubMed Web of Science ®Google Scholar
• . Schiele F, Legalery P, Didier K, . Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. Am Heart J. 2006;151(3):661–667
   PubMed Web of Science ®Google Scholar
• . Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92(5):509–514
   PubMed Web of Science ®Google Scholar
• . Anavekar N, McMurray JJ, Velazquez EJ, . Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–1295
   PubMed Web of Science ®Google Scholar
• . Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138(11):917–924
   PubMed Web of Science ®Google Scholar
• . McCullough PA. Acute coronary syndromes in patients with renal failure. Curr Cardiol Rep. 2003;5(4):266–270
   PubMedGoogle Scholar
• . Stigant C, Izadnegahdar M, Levin A, Buller CE, Humphries KH. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis. 2005;45(6):1002–1009
   PubMed Web of Science ®Google Scholar
• . Bevc S, Penko M, Kanic V, Hojs R. Mortality of patient with renal dysfunction after percutaneous coronary intervention. Angiology. 2010;61(1):24–30
   PubMed Web of Science ®Google Scholar
• . Keeley EC, Kadakia R, Soman A, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92(5):509–514
   PubMed Web of Science ®Google Scholar
• . Lemos PA, Arampatzis CA, Hoye A, . Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluding stents or bare metal stents. Am J Cardiol. 2005;95(2):167–172
   PubMed Web of Science ®Google Scholar
• . Nakazawa G, Tanabe K, Aoki J, . Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv. 2007;69(6):808–814
   PubMed Web of Science ®Google Scholar
• . Ota T, Umeda H, Yokota S, . Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. Am Heart J. 2009;158(1):92–98
   PubMed Web of Science ®Google Scholar
• . Jeong YH, Hong MK, Lee CW, . Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Int J Cardiol. 2008;125(1):36–40
   PubMed Web of Science ®Google Scholar